Curre nt Co mplia nc e I ssue s in Pha rma c y Pra c tic e ME L - PDF document

10/8/2019 Curre nt Co mplia nc e I ssue s in Pha rma c y Pra c tic e ME L I SSA RE I CHE RT , PHARM.D. OK L AHOMA ST AT E BOARD OF PHARMACY, PHARMACI ST COMPL I ANCE OF F ICE R F ina nc ia l Disc lo sure a nd Re so lutio n Unde r g uide line s e sta b lishe d b y the Ac c re dita tio n Co unc il fo r Pha rma c y E duc a tio n (ACPE ), disc lo sure must b e ma de re g a rding fina nc ia l re la tio nships with c o mme rc ia l inte re sts within the la st 12 mo nths.  I ha ve no re le va nt fina nc ia l re la tio nships o r a ffilia tio ns with c o mme rc ia l inte re sts to disc lo se . 1

10/8/2019 L e a rning Ob je c tive s  At the c o mple tio n o f this a c tivity, pha rma c ists will b e a b le to :  Re c o g nize c o mmo n c o mplia nc e issue s prio r to a n Okla ho ma Sta te Bo a rd o f Pha rma c y inspe c tio n.  E xpla in the c o rre la tio n b e twe e n pra c tic e site c o mplia nc e a nd pa tie nt sa fe ty. Pre -Asse ssme nt Que stio n 1  Wha t drug ma y a no n-Okla ho ma lic e nse d o ut-o f-sta te physic ia n a ssista nt pre sc rib e ?  A. T ra ma do l  B. Alpra zo la m  C. Pro pra no lo l  D. Ac e ta mino phe n with Co de ine 2

10/8/2019 Pre -Asse ssme nt Que stio n 2  Ho w o fte n ma y a pa tie nt re q ue st a print o ut o f the ir PMP re po rt fro m the pha rma c ist?  A. Annua lly  B. Se mi-a nnua lly  C. Ne ve r  D. One -time o nly Pre -Asse ssme nt Que stio n 3  Whe n must a CDS inve nto ry b e ta ke n?  A. Cha ng e o f lo c a tio n  B. Cha ng e o f pha rma c y na me  C. Bi-a nnua lly  D. Cha ng e o f o wne rship 3

10/8/2019 Pre -Asse ssme nt Que stio n 4  Wha t is the missio n o f the Okla ho ma Bo a rd o f Pha rma c y?  A. Pro te c t pha rma c ists  B. Pro te c t physic ia ns  C. Pro te c t c itize ns o f Okla ho ma  D. Pro te c t pha rma c y te c hnic ia ns Na tio na l Drug Co de (NDC)  T he NDC dispe nse d to the pa tie nt sho uld ma tc h the NDC b ille d to insura nc e .  F ra udule nt b illing  I nsura nc e a udits 4

10/8/2019 T e mpe ra ture L o g s  Re frig e ra to r a nd fre e ze r  I mmuniza tio ns  Othe r te mpe ra ture se nsitive me dic a tio ns  T wic e da ily  Pro pe r te mpe ra ture ra ng e s  Re c o rd e xc ursio ns  E le c tro nic lo g g ing Out o f Sta te Mid-L e ve l Pra c titio ne rs  No n-CDS a llo we d  CDS unc ha ng e d-Okla ho ma lic e nse re q uire d fo r b o th mid-le ve l pra c titio ne r a nd supe rvising physic ia n 5

10/8/2019 Pha rma c y T e c hnic ia ns  Must ha ve pe rmit sig ne d b y c urre nt e mplo ye r  Must ha ve initia l tra ining a nd a nnua l tra ining  Bo a rd o f Pha rma c y te c hnic ia n e xa m  I f tra ining o nline , must print o r ha ve a b ility o n inspe c tio n to lo g in to a ll te c hnic ia n pro file s  T e c hnic ia n tra ining do c ume nts o n Bo a rd o f Pha rma c y we b site Offic e Use Co mpo unds  No lo ng e r a llo we d fo r re ta il pha rma c ie s b y F DA 6

10/8/2019 CDS I nvo ic e s  Ve rify q ua ntity  Da te DE A Numb e rs fo r Physic ia ns  Multiple fo r e a c h sta te he / she pra c tic e s  Pha rma c ists must ve rify the a ppro pria te DE A is use d  DE A fine s 7

10/8/2019 CBD  Do yo u ha ve the Ce rtific a te o f Ana lysis? HB 2931  All CDS Rxs must b e e le c tro nic b y Ja n 1, 2020  T he re a re e xc e ptio ns 8

10/8/2019 PMP  Ca nno t b e g ive n to the pa tie nt  Ca nno t b e use d fo r yo ur o wn pe rso na l inve stig a tive purpo se s Re turn-to -Sto c k Bo ttle s  Must ha ve a drug e xpira tio n da te  One ye a r o r le ss pe r USP 9

10/8/2019 T he ft  Bo a rd must b e no tifie d o f a ny the ft  DE A 106  OBNDD  Administra tio n  Othe r Bo a rds  No tific a tio n re q uire d re g a rdle ss o f c a use  I f yo u suspe c t so me thing , a lwa ys re po rt it HB 2039  Ma inte na nc e me dic a tio ns  Re fills must b e a utho rize d b y pre sc rib e r  Ma y dispe nse up to 90 da y supply  Only o n no n-CDS  Use pro fe ssio na l judg me nt 10

10/8/2019 No n-CDS invo ic e s  Ma y b e sto re d e le c tro nic a lly  CDS-still must ha ve pa pe r c o py due to c he c k-in pro c e sse s I nspe c tio n Re po rts  K e e p until ne xt Bo a rd inspe c tio n  Must a ddre ss a ll c o rre c tio ns ma de imme dia te ly  Sa mple s o n o ur we b site 11

10/8/2019 F lo a ting Pha rma c ists  Pha rma c ist lic e nse  I mmuniza tio n c e rtific a te  CPR USP 800  De c e mb e r 2019  Bo a rd o f Pha rma c y rule s will no t g o into e ffe c t this ye a r 12

10/8/2019 I de ntific a tio n Re q uire me nts  T e c hs/ c le rks must we a r a n ide ntific a tio n b a dg e sta ting the ir po sitio n  I f wo rk multiple po sitio ns, must ha ve multiple ide ntific a tio n b a dg e s  Must a lso ide ntify the mse lve s o n the pho ne CDS I nve nto ry  Must ha ve c o py o f a nnua l inve nto ry in pha rma c y fo r inspe c tio n  DE A c o py  I f PI C c ha ng e , c ha ng e o f o wne r, o r c lo sing 13

10/8/2019 Bo a rd o f Pha rma c y We b site  Anno unc e me nts  Ne wsle tte rs  F AQs  Additio na l Re so urc e s Missio n  Pro te c t the he a lth, sa fe ty, a nd we lfa re o f the c itize ns o f Okla ho ma  Sa fe ty  Dive rsio n  Co mmitte e s  L e t yo ur vo ic e b e he a rd! 14

10/8/2019 Po st-Asse ssme nt Que stio n 1  Wha t drug ma y a no n-Okla ho ma lic e nse d o ut-o f-sta te physic ia n a ssista nt pre sc rib e ?  A. T ra ma do l  B. Alpra zo la m  C. Pro pra no lo l  D. Ac e ta mino phe n with Co de ine Po st-Asse ssme nt Que stio n 2  Ho w o fte n ma y a pa tie nt re q ue st a print o ut o f the ir PMP re po rt fro m the pha rma c ist?  A. Annua lly  B. Se mi-a nnua lly  C. Ne ve r  D. One -time o nly 15

10/8/2019 Po st-Asse ssme nt Que stio n 3  Whe n must a CDS inve nto ry b e ta ke n?  A. Cha ng e o f lo c a tio n  B. Cha ng e o f pha rma c y na me  C. Bi-a nnua lly  D. Cha ng e o f o wne rship Po st-Asse ssme nt Que stio n 4  Wha t is the missio n o f the Okla ho ma Bo a rd o f Pha rma c y?  A. Pro te c t pha rma c ists  B. Pro te c t physic ia ns  C. Pro te c t c itize ns o f Okla ho ma  D. Pro te c t pha rma c y te c hnic ia ns 16

10/8/2019 I n Summa ry…  Ple a se re a d ne wsle tte rs a nd a nno unc e me nts to sta y up-to -da te with c urre nt c o mplia nc e issue s.  Ne ve r he sita te to c a ll the Bo a rd o f Pha rma c y o ffic e , a nd a sk to spe a k to a c o mplia nc e o ffic e r.  Re vie w sa mple inspe c tio n fo rms to e nsure c o mplia nc e prio r to yo ur Bo a rd o f Pha rma c y inspe c tio n.  Alwa ys ma ke a ll c o rre c tio ns re q uire d.  Be pre pa re d, no t sc a re d! Que stio ns?  Me lissa Re ic he rt, Pha rma c ist Co mplia nc e Offic e r  mre ic he rt@ pha rma c y.o k.g o v  918-671-9025 (c e ll) 17

10/8/2019 Curre nt Co mplia nc e I ssue s in Pha rma c y Pra c tic e ME L I SSA RE I CHE RT , PHARM.D. OK L AHOMA ST AT E BOARD OF PHARMACY, PHARMACI ST COMPL I ANCE OF F ICE R 18